<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Intraoperative use of vasoactive agents
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Intraoperative use of vasoactive agents
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Intraoperative use of vasoactive agents
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin J London, MD, FASE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Girish P Joshi, MB, BS, MD, FFARCSI
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan B Mark, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nancy A Nussmeier, MD, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2045250371">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intraoperative episodes of hypotension and hypertension are common due to the effects of anesthetic agents and techniques, surgical manipulations, and the patient's medical comorbidities. This topic discusses the vasoactive agents (eg, vasopressors, inotropes, antihypertensive agents) that are commonly used to treat these intraoperative episodes.
        </p>
        <p>
         A separate topic discusses the physiologic principles, complications, and controversies surrounding use of intravenous (IV) vasopressors and inotropes. (See
         <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">
          "Use of vasopressors and inotropes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">
          "Drugs used for the treatment of hypertensive emergencies", section on 'Parenteral drugs'
         </a>
         .)
        </p>
        <p>
         Use of IV antihypertensive agents to treat hypertensive emergencies in other settings is discussed in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">
          "Use of vasopressors and inotropes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">
          "Drugs used for the treatment of hypertensive emergencies", section on 'Parenteral drugs'
         </a>
         .)
        </p>
        <p>
         Prevention, diagnosis, and treatment of intraoperative hemodynamic aberrations (eg, hypotension, hypertension, tachycardia, bradycardia) are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/94532.html" rel="external">
          "Hemodynamic management during anesthesia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1663509081">
         <span class="h1">
          VASOPRESSOR AND POSITIVE INOTROPIC AGENTS
         </span>
        </p>
        <p class="headingAnchor" id="H1626270936">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bolus doses or continuous infusions of vasopressor or inotropic agents are administered to treat hypotension that does not immediately respond to decreasing anesthetic depth administration of fluid  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef63100" href="/z/d/graphic/63100.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/94532.html" rel="external">
          "Hemodynamic management during anesthesia in adults", section on 'Hypotension: Prevention and treatment'
         </a>
         ). Vasopressors raise blood pressure (BP) by increasing systemic vascular resistance (SVR), whereas inotropic (and positive chronotropic) agents increase contractility and heart rate (HR) to increase cardiac output (CO). Many agents have both vasopressor and inotropic effects. However, the anesthesiologist is not directly measuring effects on CO unless a pulmonary artery catheter or other CO monitoring device is in place. (See
         <a class="medical medical_review" href="/z/d/html/1595.html" rel="external">
          "Pulmonary artery catheterization: Interpretation of hemodynamic values and waveforms in adults", section on 'Calculation of cardiac output'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/107337.html" rel="external">
          "Novel tools for hemodynamic monitoring in critically ill patients with shock", section on 'Cardiac output'
         </a>
         .)
        </p>
        <p>
         Although agents that increase BP may be necessary to treat hypotension, other causes of hypotension (eg, hypovolemia) should be identified and treated to minimize dosing and duration of vasopressor/inotropic agent administration [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p>
         Notably, agents such as
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         and epinephrine that increase HR, CO, and BP may be detrimental in selected patients with ischemic heart disease  (
         <a class="graphic graphic_table graphicRef91907" href="/z/d/graphic/91907.html" rel="external">
          table 3
         </a>
         ), or left ventricular (LV) outflow tract obstruction. (See
         <a class="medical medical_review" href="/z/d/html/90616.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with ischemic heart disease", section on 'Prevention of ischemia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114418.html" rel="external">
          "Anesthesia for patients with hypertrophic cardiomyopathy undergoing noncardiac surgery"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4016638963">
         <span class="h2">
          Adrenergic agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">
          "Use of vasopressors and inotropes", section on 'Adrenergic agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2410424372">
         <span class="h3">
          Ephedrine
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General considerations
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          Ephedrine
         </a>
         is administered in 5 to 10 mg bolus doses. It is often selected as a first-line agent to treat acute decreases in BP, particularly if bradycardia is present. Ephedrine stimulates alpha, beta
         <sub>
          1
         </sub>
         , and beta
         <sub>
          2
         </sub>
         receptors; thus, it has vasopressor, inotropic, and chronotropic properties. These are primarily indirect effects that include presynaptic release of norepinephrine, as well as postsynaptic release and inhibition of norepinephrine uptake [
         <a href="#rid4">
          4-6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advantages
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Increases in BP, HR, and CO are beneficial in most patients with hypotension, particularly if bradycardia originating within or above the atrioventricular node is present (eg, due to beta blocking agents).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bronchodilating beta
         <sub>
          2
         </sub>
         effects are beneficial if bronchospasm is present [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Duration of action is typically longer than equipotent small bolus doses of epinephrine.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cerebral blood flow and cerebral oxygenation are better preserved compared with
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         [
         <a href="#rid8">
          8-11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disadvantages
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tachyphylaxis may occur with repeated doses or in patients with depleted stores of endogenous norepinephrine (eg, those with hemorrhagic shock). Typically, another agent is added or substituted for
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         after 50 to 60 mg have been administered [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Attenuation of the cardiovascular effects of
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         occurs if it is coadministered with agents that block ephedrine uptake into adrenergic nerves (eg, cocaine) or deplete norepinephrine reserves (eg,
         <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">
          prazosin
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An exaggerated hypertensive response or life-threatening dysrhythmias may occur following administration of
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         to patients chronically receiving:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Monoamine oxidase inhibitors – (See
         <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">
          "Perioperative medication management", section on 'Monoamine oxidase inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Methamphetamines – (See
         <a class="medical medical_review" href="/z/d/html/139188.html" rel="external">
          "Anesthesia for patients with substance use disorder or acute intoxication", section on 'Amphetamines and similar agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Selected hallucinogens – (See
         <a class="medical medical_review" href="/z/d/html/139188.html" rel="external">
          "Anesthesia for patients with substance use disorder or acute intoxication", section on 'Hallucinogens and dissociative drugs'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Thus,
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         is avoided or administered in very small incremental doses of 2.5 mg in these patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use in obstetrical anesthesia may be associated with increased risk of fetal acidosis. (See
         <a class="medical medical_review" href="/z/d/html/4480.html" rel="external">
          "Anesthesia for cesarean delivery", section on 'Vasopressors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rare allergic reactions such as delayed severe dermatitis may occur following intravenous (IV) injection [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Administration as a continuous infusion is not possible.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2359073959">
         <span class="h3">
          Phenylephrine
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General considerations
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          Phenylephrine
         </a>
         may be administered in bolus doses (eg, 50 to 100 mcg) or as a continuous infusion at 10 to 100 mcg/minute. It is often selected to treat hypotension if normal or elevated HR is present. Phenylephrine causes vasoconstriction by exclusively stimulating alpha
         <sub>
          1
         </sub>
         -adrenergic receptors and is usually associated with baroreceptor reflex-mediated decreases in HR. It is the most commonly selected intraoperative vasopressor in the United States.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advantages
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A decreased or stable HR is desirable in patients with ischemic heart disease  (
         <a class="graphic graphic_table graphicRef91907" href="/z/d/graphic/91907.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid14">
          14-16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/90616.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with ischemic heart disease", section on 'Prevention of ischemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vasoconstrictor agents with primarily alpha
         <sub>
          1
         </sub>
         agonist properties such as
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         do not have positive inotropic or chronotropic properties. Such agents are the best initial treatment options for hypotension in patients with LV outflow tract obstruction, aortic stenosis, or tetralogy of Fallot. (See
         <a class="medical medical_review" href="/z/d/html/114418.html" rel="external">
          "Anesthesia for patients with hypertrophic cardiomyopathy undergoing noncardiac surgery"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/93514.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with aortic or mitral valve disease", section on 'Hemodynamic management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/99944.html" rel="external">
          "Anesthesia for adults with congenital heart disease undergoing noncardiac surgery", section on 'Right-to-left shunt with cyanosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          Phenylephrine
         </a>
         may be administered in bolus doses or as a continuous infusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disadvantages
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individual responses may be variable due to variations in vascular responsiveness to
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         [
         <a href="#rid17">
          17-19
         </a>
         ]. For example, genomic studies of polymorphisms of the beta
         <sub>
          2
         </sub>
         -adrenergic receptor suggest that selected patients (eg, Gly16 carriers) may require larger doses of intraoperative vasopressors such as phenylephrine or
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         due to association of the Gly16 allele with vasodilation and higher CO compared with other genotypes [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Alpha
         <sub>
          1
         </sub>
         receptor-mediated vasoconstriction caused by
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         may reduce CO due to decreased stroke volume and arterial compliance [
         <a href="#rid21">
          21-23
         </a>
         ]. Although
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         and norepinephrine also cause arterial vasoconstriction, these agents also have positive inotropic effects and ephedrine may also increase HR, with likely increases in CO [
         <a href="#rid21">
          21,24-27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14942.html" rel="external">
          "Intraoperative fluid management", section on 'Dynamic parameters to assess volume responsiveness'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vasoconstriction with decreases in HR is detrimental in selected patients (eg, those with aortic or mitral regurgitation). (See
         <a class="medical medical_review" href="/z/d/html/93514.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with aortic or mitral valve disease", section on 'Aortic regurgitation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/93514.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with aortic or mitral valve disease", section on 'Mitral regurgitation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Effectiveness may be limited in patients with impaired ventricular function and chronic heart failure due to decreased alpha
         <sub>
          1
         </sub>
         receptor responsiveness.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The effects of alpha-mediated vasoconstriction on splanchnic blood volumes and venous return are complex and may not always be beneficial [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         As with
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         , rare localized allergic reaction may occur.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4191147455">
         <span class="h3">
          Norepinephrine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Norepinephrine is an endogenous catecholamine that may be administered in bolus doses of 4 to 8 mcg or as a continuous infusion at 1 to 20 mcg/minute. It is used for treatment of most types of shock and is commonly used in patients undergoing cardiac surgery (see
         <a class="medical medical_review" href="/z/d/html/94164.html" rel="external">
          "Intraoperative management of shock in adults", section on 'Initial resuscitation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/115472.html" rel="external">
          "Intraoperative problems after cardiopulmonary bypass", section on 'Vasoactive drug therapy'
         </a>
         ). Furthermore, its use as a first-line agent during noncardiac surgery is increasing as infusion via a peripheral IV catheter has become more widely accepted [
         <a href="#rid12">
          12,28-33
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advantages
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Norepinephrine has positive inotropic effects that maintain or increase CO in most patients, while simultaneously causing arterial vasoconstriction and increasing BP [
         <a href="#rid25">
          25,29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Compared with
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         , 8 mcg norepinephrine is approximately equipotent to 100 mcg of phenylephrine [
         <a href="#rid34">
          34
         </a>
         ]. At comparable doses, norepinephrine is more likely to increase BP without significantly decreasing stroke volume or arterial compliance [
         <a href="#rid21">
          21,25,35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Limited data also support the safety and efficacy of norepinephrine in obstetrical anesthesia [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4480.html" rel="external">
          "Anesthesia for cesarean delivery", section on 'Vasopressors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Norepinephrine may be administered in bolus doses or as a continuous infusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disadvantages
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Like
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         , norepinephrine-induced alpha
         <sub>
          1
         </sub>
         receptor-mediated vasoconstriction may reduce CO in some patients. However, in patients who demonstrate fluid responsiveness (see
         <a class="medical medical_review" href="/z/d/html/14942.html" rel="external">
          "Intraoperative fluid management", section on 'Dynamic parameters to assess volume responsiveness'
         </a>
         ), administration of norepinephrine can increase CO due to greater venous return leading to increased preload [
         <a href="#rid25">
          25
         </a>
         ], as well as its positive inotropic effects.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A central venous catheter (CVC) or peripherally inserted central catheter is usually employed for prolonged administration of norepinephrine due to concern regarding tissue damage if peripheral extravasation occurs. However, since small doses of norepinephrine may be effective for initial treatment of hypotension, dilute solutions containing norepinephrine 4 to 8 mcg/mL can be administered as a bolus when necessary [
         <a href="#rid34">
          34,37
         </a>
         ]. One randomized trial that included 3626 patients compared administration of norepinephrine in a concentration of 8 to 32 mcg/mL versus
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         100 mcg/mL as the first-line vasopressor to be infused for treatment of hypotension whether the patient had a CVC [
         <a href="#rid33">
          33
         </a>
         ]. Cardiovascular and renal outcomes were similar between the groups. No episodes of extravascular extravasation were reported. A larger retrospective study that included 14,385 patients who received a norepinephrine infusion of 20 mcg/mL via peripheral IV catheters noted a low incidence of extravasation in five patients (0.035 percent); none required surgical or medical intervention [
         <a href="#rid38">
          38
         </a>
         ]. Other reviews have also noted that dilute solutions of norepinephrine and other vasopressors rarely cause tissue damage when administered through a free-flowing peripheral IV catheter [
         <a href="#rid39">
          39-41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The optimal position in the arm for a peripheral IV catheter is the basilic or cephalic vein. In a systematic review of 325 extravasation and local tissue injury events that occurred during vasopressor infusions in critically ill patients, more than 85 percent occurred at an infusion site located distal to the antecubital fossa in the upper extremity, or distal to the popliteal fossa in the lower extremity [
         <a href="#rid39">
          39
         </a>
         ]. However, catheterization of the basilic or cephalic vein directly in the antecubital fossa is avoided if possible since this position has the potential for penetration of the vein with arm flexion [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3381811837">
         <span class="h3">
          Epinephrine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epinephrine is an endogenous catecholamine, which is converted from norepinephrine by phenylethanolamine-N-methyltransferase in the adrenal medulla. It is used as a first-line agent to treat severe intraoperative hypotension due to anaphylaxis or cardiac arrest  (
         <a class="graphic graphic_table graphicRef107933" href="/z/d/graphic/107933.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef129983" href="/z/d/graphic/129983.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2077.html" rel="external">
          "Perioperative anaphylaxis: Clinical manifestations, etiology, and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults"
         </a>
         .)
        </p>
        <p>
         Epinephrine may also be safely used in low bolus doses of 8 to 16 mcg to treat less severe episodes of intraoperative hypotension occurring during cardiac or noncardiac surgery. Notably, epinephrine is more typically administered as an infusion, particularly if repeated bolus doses are necessary. In low-dose infusions of approximately 1 to 2 mcg/minute (ie, 0.01 to 0.02 mcg/kg per minute in a 100 kg patient), epinephrine has primarily beta
         <sub>
          2
         </sub>
         -adrenergic effects with beneficial bronchodilator effects and arterial vasodilation rather than vasoconstriction. Intermediate dose ranges of approximately 2 to 10 mcg/minute (ie, 0.02 to 0.1 mcg/kg per minute) primarily cause predominant beta
         <sub>
          1
         </sub>
         and beta
         <sub>
          2
         </sub>
         -adrenergic effects as well as some alpha-adrenergic effects, resulting in increased BP and HR, as well as bronchodilation. At higher doses of approximately 10 to 100 mcg/minute (ie, 0.1 to 1 mcg/kg per minute), epinephrine has primarily alpha-adrenergic effects causing vasoconstriction with possible hypertension. Notably, individual responses to dose-related effects are variable.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advantages
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         As a first-line therapy for cardiac arrest and for anaphylaxis, epinephrine may be administered via an intramuscular (IM) route or through an endotracheal tube if IV access is unavailable or lost during such emergencies. (See
         <a class="medical medical_review" href="/z/d/html/392.html" rel="external">
          "Anaphylaxis: Emergency treatment", section on 'Epinephrine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Epinephrine may be administered in bolus doses or as a continuous infusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disadvantages
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Titrating the balance between the alpha and beta receptor effects of epinephrine can be challenging due to interindividual variability in dose-related responses.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Large bolus doses of epinephrine may cause profound hypertension primarily owing to its alpha effects.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adverse metabolic effects of excessive beta
         <sub>
          2
         </sub>
         stimulation include hyperglycemia, lipolysis, and metabolic acidosis (due to type B lactic acidosis) [
         <a href="#rid42">
          42,43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H962380008">
         <span class="h2">
          Vasopressin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vasopressin (antidiuretic hormone [ADH]) is typically used to treat hypotension that is refractory to administration of adrenergic agents, particularly for patients with vasoplegia (eg, septic shock)  (
         <a class="graphic graphic_table graphicRef126194" href="/z/d/graphic/126194.html" rel="external">
          table 5
         </a>
         ). Vasopressin is a naturally occurring nonapeptide essential for maintenance of plasma osmolality due to its antidiuretic actions. It also acts as a vasoconstrictor by stimulating the nonadrenergic V1 receptor if administered in supraphysiologic concentrations (eg, bolus doses of 1 to 4 units or as a continuous infusion at 0.01 to 0.04 units/minute). It is often added as a supplementary agent after an inadequate response to other vasopressors. Higher vasopressin doses up to 0.1 units/minute are reserved for instances when a mean arterial BP goal cannot be achieved with lower vasopressin doses in combination with other vasopressor agents [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         Although efficacy of vasopressin is relatively equivalent to equipotent doses of epinephrine in producing profound arterial vasoconstriction, epinephrine is strongly preferred as the first-line vasopressor during advanced cardiovascular life support during cardiac arrest  (
         <a class="graphic graphic_algorithm graphicRef129983" href="/z/d/graphic/129983.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">
          "Use of vasopressors and inotropes", section on 'Vasopressin and analogs'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94164.html" rel="external">
          "Intraoperative management of shock in adults", section on 'Distributive shock management'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advantages
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vasopressin is effective for treatment of hypotension refractory to administration of adrenergic agents (eg,
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         , norepinephrine, epinephrine  (
         <a class="graphic graphic_table graphicRef126194" href="/z/d/graphic/126194.html" rel="external">
          table 5
         </a>
         )). Examples include vasoplegia due to sepsis, chronic administration of angiotensin-converting enzyme inhibitors, or prolonged cardiopulmonary bypass (CPB) [
         <a href="#rid44">
          44,45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/115472.html" rel="external">
          "Intraoperative problems after cardiopulmonary bypass", section on 'Vasoplegia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94164.html" rel="external">
          "Intraoperative management of shock in adults", section on 'Distributive shock management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vasopressin has no direct effects on HR; a slower HR is desirable in patients with ischemic heart disease  (
         <a class="graphic graphic_table graphicRef91907" href="/z/d/graphic/91907.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/90616.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with ischemic heart disease", section on 'Prevention of ischemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vasopressin has no vasoconstrictive effect on pulmonary arteries; thus, it is the preferred agent in patients with pulmonary hypertension [
         <a href="#rid46">
          46-48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94362.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with pulmonary hypertension or right heart failure", section on 'Vasopressors and inotropes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An agent with pure vasoconstrictor activity such as vasopressin is the best option for patients with LV outflow tract obstruction, aortic stenosis, or tetralogy of Fallot when treatment with a vasopressor is necessary:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/114418.html" rel="external">
          "Anesthesia for patients with hypertrophic cardiomyopathy undergoing noncardiac surgery", section on 'Hemodynamic goals and management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/93514.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with aortic or mitral valve disease", section on 'Hemodynamic management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/99944.html" rel="external">
          "Anesthesia for adults with congenital heart disease undergoing noncardiac surgery", section on 'Right-to-left shunt with cyanosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vasopressin may be administered in bolus doses or as a continuous infusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disadvantages
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Peripheral extravasation of vasopressin can cause skin necrosis [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The half-life of vasopressin is longer than that of
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         or the catecholamines (norepinephrine and epinephrine). Thus, vasopressin is more difficult to titrate.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vasopressin is usually avoided in patients with neurologic injury and in those undergoing craniotomy because it can cause cerebral vasoconstriction [
         <a href="#rid50">
          50
         </a>
         ]. However, it may be used if hypotension is refractory to adrenergic agents. (See
         <a class="medical medical_review" href="/z/d/html/93391.html" rel="external">
          "Anesthesia for craniotomy in adults", section on 'Vasoactive drugs'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Since vasopressin may cause selective splanchnic arteriolar vasoconstriction, it is used cautiously in patients at risk for splanchnic hypoperfusion [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1543643813">
         <span class="h2">
          Other agents to treat refractory vasoplegia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infusions of other vasopressors may be necessary to treat vasoplegia that is unresponsive to high doses of norepinephrine and/or vasopressin [
         <a href="#rid51">
          51
         </a>
         ]. These include
         <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">
          methylene blue
         </a>
         [
         <a href="#rid52">
          52-54
         </a>
         ], angiotensin II [
         <a href="#rid52">
          52,55-57
         </a>
         ],
         <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">
          vitamin C
         </a>
         [
         <a href="#rid52">
          52,58,59
         </a>
         ], and hydroxycobalamin  (
         <a class="graphic graphic_table graphicRef126194" href="/z/d/graphic/126194.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid52">
          52-54
         </a>
         ]. However, none of these are the first-line treatment for intraoperative hypotension. (See
         <a class="medical medical_review" href="/z/d/html/94164.html" rel="external">
          "Intraoperative management of shock in adults", section on 'Distributive shock management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H437713730">
         <span class="h2">
          Other inotropic agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infusions of other inotropic drugs may be used to support the circulation in selected patients. These are not first-line vasoactive agents for treatment of intraoperative hypotension or other hemodynamic abnormalities in the intraoperative setting. Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other adrenergic agents  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dopamine – The hemodynamic effects of dopamine are dose dependent. Its predominant actions are on dopamine-1 receptors resulting in selective vasodilation at low doses, on beta
         <sub>
          1
         </sub>
         -adrenergic receptors resulting in inotropic and chronotropic effects at higher doses, and on alpha-adrenergic receptors resulting in vasoconstriction at the highest doses. Dopamine may be selected as a second-line alternative to norepinephrine in patients with bradycardia. Details are discussed in separate topics. (See
         <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">
          "Use of vasopressors and inotropes", section on 'Dopamine'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3488.html" rel="external">
          "Inotropic agents in heart failure with reduced ejection fraction", section on 'Dopamine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dobutamine –
         <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">
          Dobutamine
         </a>
         is an adrenergic agent that has inotropic, chronotropic, and overall vasodilatory properties. Details are discussed in separate topics. (See
         <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">
          "Use of vasopressors and inotropes", section on 'Dobutamine'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3488.html" rel="external">
          "Inotropic agents in heart failure with reduced ejection fraction", section on 'Dobutamine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Isoproterenol –
         <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">
          Isoproterenol
         </a>
         is an inotropic and chronotropic agent that is not a vasopressor. Mechanisms of action, indications, and contraindications are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">
          "Use of vasopressors and inotropes", section on 'Isoproterenol'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other inodilator agents that decrease rather than increase BP (eg,
         <a class="drug drug_general" data-topicid="9652" href="/z/d/drug information/9652.html" rel="external">
          milrinone
         </a>
         , levosimendan) as discussed below  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Inodilators'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H379680608">
         <span class="h1">
          ANTIHYPERTENSIVE AGENTS
         </span>
        </p>
        <p class="headingAnchor" id="H3699481896">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bolus doses and/or continuous infusions of antihypertensive agents may be administered to treat hypertension  (
         <a class="graphic graphic_table graphicRef119750" href="/z/d/graphic/119750.html" rel="external">
          table 6
         </a>
         ) if there is insufficient response to rapid increases in anesthetic depth, administration of analgesic agents, or removal of noxious stimuli (eg, surgical pain, presence of an endotracheal tube). If increases in blood pressure (BP) are thought to be due to interruption of the patient's chronic antihypertensive regimen on the day of surgery, treatment with an intravenous (IV) equivalent of the missed medication is ideal, particularly if that medication was a beta blocker or
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/94355.html" rel="external">
          "Anesthesia for patients with hypertension", section on 'Antihypertensive medication withdrawal'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3868.html" rel="external">
          "Perioperative management of hypertension", section on 'Withdrawal syndromes'
         </a>
         .)
        </p>
        <p>
         Caution is exercised during administration of any antihypertensive agents to:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with hypovolemia. Precipitous hypotension may result after administration of any antihypertensive agent, particularly those that reduce preload (eg,
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">
          nitroprusside
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with increased intracranial pressure (ICP). Most vasodilating agents (eg,
         <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">
          nitroprusside
         </a>
         ,
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">
          hydralazine
         </a>
         , calcium channel blockers,
         <a class="drug drug_general" data-topicid="8629" href="/z/d/drug information/8629.html" rel="external">
          fenoldopam
         </a>
         ) dilate the cerebral circulation and can increase cerebral flow and ICP. (See
         <a class="medical medical_review" href="/z/d/html/93391.html" rel="external">
          "Anesthesia for craniotomy in adults", section on 'Vasoactive drugs'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H595440830">
         <span class="h2">
          Beta blockers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypertension associated with increased heart rate (HR) and/or cardiac output (CO) is typically treated with bolus doses of a beta blocker (eg,
         <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">
          labetalol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         )  (
         <a class="graphic graphic_table graphicRef119750" href="/z/d/graphic/119750.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">
          "Drugs used for the treatment of hypertensive emergencies", section on 'Adrenergic-blocking agents'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advantages
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Decreases in HR and BP are beneficial in patients with ischemic heart disease if tachycardia and/or hypertension are present  (
         <a class="graphic graphic_table graphicRef91907" href="/z/d/graphic/91907.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/90616.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with ischemic heart disease", section on 'Prevention of ischemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients chronically receiving a beta blocker as part of an antihypertensive or antianginal regimen, administration of a beta blocker is an effective first-line treatment. Notably, if a beta blocker dose was missed on the day of surgery, rebound hypertension may occur. (See
         <a class="medical medical_review" href="/z/d/html/3864.html" rel="external">
          "Tapering and discontinuing antihypertensive medications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3868.html" rel="external">
          "Perioperative management of hypertension", section on 'Withdrawal syndromes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disadvantages
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Beta blockers should be avoided in patients with:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Significant hypovolemia or acute hemorrhage causing anemia [
         <a href="#rid60">
          60,61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Decompensated heart failure. (See
         <a class="medical medical_review" href="/z/d/html/3450.html" rel="external">
          "Treatment of acute decompensated heart failure: Specific therapies", section on 'Approach to long-term therapy in hospitalized patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Acute or severe bronchospastic lung disease. (See
         <a class="medical medical_review" href="/z/d/html/1437.html" rel="external">
          "Management of the patient with COPD and cardiovascular disease", section on 'Effects of beta-blockers on mortality and COPD exacerbations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Severe sinus bradycardia or a markedly impaired cardiac conduction system (eg, sinus node dysfunction or advanced atrioventricular block).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Beta blockers are relatively contraindicated in patients with cocaine intoxication owing to the risk of inducing unopposed alpha-adrenergic stimulation, which may lead to hypertension and myocardial ischemia from coronary vasoconstriction. (See
         <a class="medical medical_review" href="/z/d/html/303.html" rel="external">
          "Cocaine: Acute intoxication", section on 'Use of beta adrenergic antagonists (beta blockers)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4022715857">
         <span class="h3">
          Labetalol
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">
          Labetalol
         </a>
         administered in 5 to 10 mg boluses up to 25 mg is a particularly good choice in patients with concomitant tachycardia and hypertension because it causes nonselective blockade of beta-adrenergic receptors and selective blockade of postsynaptic alpha
         <sub>
          1
         </sub>
         -adrenergic receptors [
         <a href="#rid62">
          62
         </a>
         ]. It is often selected to treat myocardial ischemia due to tachycardia when BP is elevated. Continuous infusions of labetalol are generally reserved for hypertensive emergencies. (See
         <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">
          "Drugs used for the treatment of hypertensive emergencies", section on 'Labetalol'
         </a>
         .)
        </p>
        <p>
         However,
         <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">
          labetalol
         </a>
         is relatively contraindicated for patients with severe asthma, chronic obstructive lung disease, heart failure, or bradycardia without hypertension. Furthermore, labetalol is avoided in hyperadrenergic states caused by pheochromocytoma or cocaine or methamphetamine overdose due to risk of severe hypertension from incomplete alpha blockade.
        </p>
        <p class="headingAnchor" id="H1241216890">
         <span class="h3">
          Esmolol
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          Esmolol
         </a>
         may be administered in 10 to 50 mg boluses. For persistent tachycardia and hypertension, an esmolol infusion at 50 to 300 mcg/minute is appropriate. Esmolol is a very cardioselective beta
         <sub>
          1
         </sub>
         blocker that has rapid onset, short duration of action, and clinical effects lasting approximately 10 to 15 minutes [
         <a href="#rid63">
          63
         </a>
         ]. Clearance is not dependent on renal or hepatic function because rapid metabolism by plasma esterases results in a short duration of action after discontinuation of the infusion. (See
         <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">
          "Drugs used for the treatment of hypertensive emergencies", section on 'Esmolol'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1084188936">
         <span class="h3">
          Metoprolol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Another option to treat persistent tachycardia and hypertension is administration of boluses of 1 to 5 mg of the longer-acting cardioselective beta
         <sub>
          1
         </sub>
         blocker
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         , followed by 2.5 to 15 mg every 3 to 6 hours. However, metoprolol cannot be administered as an infusion and does not have rapid offset. These properties may be a disadvantage if conditions are unstable during the intraoperative period (eg, due to bleeding). Nevertheless, metoprolol is often the preferred agent during the early postoperative period because of its longer duration of action compared with other IV beta blockers and the convenience of bolus dosing.
        </p>
        <p class="headingAnchor" id="H257875843">
         <span class="h3">
          Landiolol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Landiolol is a short-acting IV beta blocker with similar kinetics but greater negative chronotropic effects than
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         due to more selective beta
         <sub>
          1
         </sub>
         effects; however, landiolol is not available in the United States [
         <a href="#rid63">
          63,64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2731344652">
         <span class="h2">
          Calcium channel blocking agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Selective dihydropyridine-type calcium channel blockers (eg,
         <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">
          nicardipine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8911" href="/z/d/drug information/8911.html" rel="external">
          clevidipine
         </a>
         ) inhibit calcium influx to provide selective arteriolar smooth muscle relaxation  (
         <a class="graphic graphic_table graphicRef119750" href="/z/d/graphic/119750.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advantages
         </strong>
         –
         <strong>
         </strong>
         Calcium channel blockers effectively treat increased BP due to increased systemic vascular resistance (SVR); they are used in the absence of tachycardia. (See
         <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">
          "Drugs used for the treatment of hypertensive emergencies", section on 'Calcium channel blockers'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disadvantages
         </strong>
         –
         <strong>
         </strong>
         These agents have no atrioventricular nodal blocking properties, so they do not slow HR if tachycardia is present.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2869936792">
         <span class="h3">
          Nicardipine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">
          Nicardipine
         </a>
         has no major impact on preload or CO, and only minor negative inotropic action [
         <a href="#rid65">
          65
         </a>
         ]. It can be administered either by IV bolus (eg, 100 to 500 mcg increments) or by continuous infusion at 5 to 15 mg/hour. (See
         <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">
          "Drugs used for the treatment of hypertensive emergencies", section on 'Nicardipine'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">
          Nicardipine
         </a>
         has been widely used in a variety of surgical settings, including cardiac and neurosurgical settings [
         <a href="#rid62">
          62
         </a>
         ]. One study comparing nicardipine with
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         for control of postcraniotomy emergence hypertension noted similar efficacy but a greater need for a second "rescue" agent in patients receiving esmolol [
         <a href="#rid66">
          66
         </a>
         ]. Another study comparing continuous infusions of nicardipine or
         <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">
          labetalol
         </a>
         to manage hypertension after acute stroke noted similar safety and efficacy for both agents [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H927003954">
         <span class="h3">
          Clevidipine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8911" href="/z/d/drug information/8911.html" rel="external">
          Clevidipine
         </a>
         is a short-acting IV calcium channel blocker that is only administered by continuous infusion (eg, beginning at 1 to 2 mg/hour with titration up to 16 mg/hour). Clevidipine has rapid onset and rapid offset due to metabolism by plasma esterases, and clearance is not dependent on renal or hepatic function. These properties may confer an advantage over either
         <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">
          nicardipine
         </a>
         or
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         in patients requiring tight BP control within a narrow range [
         <a href="#rid68">
          68,69
         </a>
         ]. Efficacy in controlling BP in stroke patients is similar to nicardipine [
         <a href="#rid70">
          70-72
         </a>
         ]. However, clevidipine is more expensive than nicardipine, and data regarding bolus dosing are lacking. (See
         <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">
          "Drugs used for the treatment of hypertensive emergencies", section on 'Clevidipine'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1677844299">
         <span class="h2">
          Direct vasodilators
         </span>
         <span class="headingEndMark">
          —
         </span>
         Direct vasodilators (eg,
         <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">
          hydralazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">
          nitroprusside
         </a>
         ) relax vascular smooth muscle  (
         <a class="graphic graphic_table graphicRef119750" href="/z/d/graphic/119750.html" rel="external">
          table 6
         </a>
         ). Although the precise mechanisms causing vasodilation are not well established, these probably include opening of K+ channels, inhibition of inositol 1,4,5 triphosphate-induced release of calcium from smooth muscle sarcoplasmic reticulum, and stimulation of nitric oxide formation by the vascular endothelium.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advantages
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypertension is effectively treated due to decreases in SVR, and this may result in a reflex increase in HR that may be desirable in a patient with bradycardia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Decreased venous return to the heart reduces preload.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disadvantages
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with tachycardia, HR is not decreased; instead, baroreceptor-mediated reflex tachycardia may lead to undesirable further increases in HR.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         During continuous infusion of
         <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">
          nitroprusside
         </a>
         or
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         , an intra-arterial catheter is necessary to continuously monitor BP.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Splanchnic blood flow may be decreased.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1883205197">
         <span class="h3">
          Hydralazine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bolus doses (eg, 2.5 mg) of
         <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">
          hydralazine
         </a>
         are often used to treat increased BP when bradycardia is present. Repeated doses may be administered every 5 minutes up to 20 mg. Hydralazine is highly selective for arterial resistance vessels, with minimal or no effect on the venous circulation [
         <a href="#rid73">
          73
         </a>
         ]. HR may increase slightly due to activation of the baroreceptor reflex. (See
         <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">
          "Drugs used for the treatment of hypertensive emergencies", section on 'Hydralazine'
         </a>
         .)
        </p>
        <p>
         Disadvantages of
         <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">
          hydralazine
         </a>
         include its relatively slow onset compared with other IV antihypertensive agents and its less predictable antihypertensive response. Also, hydralazine cannot be administered as a continuous infusion.
        </p>
        <p class="headingAnchor" id="H185328201">
         <span class="h3">
          Nitroglycerin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          Nitroglycerin
         </a>
         is commonly selected for patients with known or suspected ischemic heart disease because it decreases BP and preload. Nitroglycerin may be administered as an IV bolus, a continuous infusion, a sublingual dose, or by application of a paste. Small bolus doses (eg, 10 to 40 mcg) or the paste formulation of nitroglycerin primarily cause venodilation, thereby reducing preload. Higher doses administered as repeated boluses or by continuous infusion at 10 to 200 mcg/minute (approximately 0.1 to 3 mcg/kg per minute) result in arteriolar dilation, thereby reducing SVR. (See
         <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">
          "Drugs used for the treatment of hypertensive emergencies", section on 'Nitroglycerin'
         </a>
         .)
        </p>
        <p>
         Disadvantages include the need for placement of an intra-arterial catheter to continuously monitor BP when a continuous infusion is administered, even though
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         is rapidly titratable. Also, nitroglycerin is not appropriate for patients with hypovolemia since venodilation further reduces preload. In addition, reflex increase in HR may occur. Increased intrapulmonary shunt has also been reported [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1584570794">
         <span class="h3">
          Nitroprusside
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">
          Nitroprusside
         </a>
         is a direct arterial vasodilator that is less commonly selected to treat severe hypertension in the intraoperative setting because safer alternative agents have been developed. It is administered by continuous infusion at 10 to 200 mcg/minute (or 0.1 to 3 mcg/kg per minute). Advantages include its potency, balanced venous and arteriolar effects, and extremely rapid onset and offset.
        </p>
        <p>
         Disadvantages include the absolute need for an intra-arterial catheter to continuously monitor BP during
         <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">
          nitroprusside
         </a>
         infusion due to its extreme potency and rapid onset of action. Also, nitroprusside should not be administered in bolus dose(s) due to the risk for precipitous severe hypotension. Also, reflex tachycardia occurs with nitroprusside administration. Other concerns include risk for cyanide accumulation from its metabolic breakdown. (See
         <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">
          "Drugs used for the treatment of hypertensive emergencies", section on 'Nitroprusside'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2010166663">
         <span class="h2">
          Inodilators
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inodilators are used in the management of acutely decompensated congestive heart failure and during and after weaning from cardiopulmonary bypass (CPB), as discussed in separate topics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3488.html" rel="external">
          "Inotropic agents in heart failure with reduced ejection fraction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3450.html" rel="external">
          "Treatment of acute decompensated heart failure: Specific therapies", section on 'Inotropic agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/115472.html" rel="external">
          "Intraoperative problems after cardiopulmonary bypass", section on 'Left ventricular dysfunction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/115472.html" rel="external">
          "Intraoperative problems after cardiopulmonary bypass", section on 'Right ventricular dysfunction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         These agents are not used as first-line vasoactive therapy in other intraoperative settings but may be selected to improve support of the circulation in patients with specific hemodynamic abnormalities  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1063921759">
         <span class="h3">
          Dobutamine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">
          Dobutamine
         </a>
         is an adrenergic agent that acts predominantly on beta
         <sub>
          1
         </sub>
         -adrenergic receptors resulting in inotropic, chronotropic, and overall vasodilation that reduces preload, afterload, and myocardial work, with or without a small reduction in BP. Details are discussed in separate topics. (See
         <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">
          "Use of vasopressors and inotropes", section on 'Dobutamine'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3488.html" rel="external">
          "Inotropic agents in heart failure with reduced ejection fraction", section on 'Dobutamine'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3821291927">
         <span class="h3">
          Milrinone
         </span>
         <span class="headingEndMark">
          —
         </span>
         The inodilator
         <a class="drug drug_general" data-topicid="9652" href="/z/d/drug information/9652.html" rel="external">
          milrinone
         </a>
         is a phosphodiesterase inhibitor that works independently of beta-adrenergic receptors, producing positive inotropic effects by slowing hydrolysis of cyclic adenosine monophosphate [
         <a href="#rid75">
          75,76
         </a>
         ]. Since administration of milrinone may result in significantly reduced SVR, concomitant use of an arterial vasoconstrictor (eg,
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         , vasopressin, norepinephrine) is typically necessary. Details are discussed in separate topics. (See
         <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">
          "Use of vasopressors and inotropes", section on 'PDE inhibitors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3488.html" rel="external">
          "Inotropic agents in heart failure with reduced ejection fraction", section on 'Intravenous phosphodiesterase-3 inhibitors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2805270069">
         <span class="h3">
          Levosimendan
         </span>
         <span class="headingEndMark">
          —
         </span>
         Levosimendan is a calcium sensitizer that acts as an inodilator by:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increasing myocardial sensitivity to calcium, which increases cardiac contractility.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Opening adenosine triphosphate (ATP)-sensitive potassium channels in vascular smooth muscle cells, causing vascular dilation that reduces preload, afterload, and myocardial work.
        </p>
        <p>
        </p>
        <p>
         This agent has not been approved for use in the United States. Details are discussed in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/3488.html" rel="external">
          "Inotropic agents in heart failure with reduced ejection fraction", section on 'Intravenous calcium-sensitizing agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2361455679">
         <span class="h2">
          Other antihypertensive agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other agents are less commonly used to lower BP in the intraoperative setting.
        </p>
        <p class="headingAnchor" id="H1908112109">
         <span class="h3">
          Dexmedetomidine and clonidine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          Clonidine
         </a>
         and
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         are alpha
         <sub>
          2
         </sub>
         -adrenoreceptor agonists with antihypertensive effects  (
         <a class="graphic graphic_table graphicRef119750" href="/z/d/graphic/119750.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dexmedetomidine
         </strong>
         <strong>
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          Dexmedetomidine
         </a>
         is commonly administered as a continuous infusion during monitored anesthesia care (MAC) or as part of a total intravenous anesthesia (TIVA) technique during general anesthesia. (See
         <a class="medical medical_review" href="/z/d/html/94529.html" rel="external">
          "Monitored anesthesia care in adults", section on 'Dexmedetomidine'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">
          "Maintenance of general anesthesia: Overview", section on 'Dexmedetomidine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Due to its sympatholytic effects, both BP and HR are typically decreased [
         <a href="#rid77">
          77,78
         </a>
         ]. For these reasons,
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         may be selected to adjust anesthetic depth in a patient with hypertension and tachycardia. For example, dexmedetomidine is a good choice if it is prudent to avoid beta blocking agents. If intraoperative
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         withdrawal is suspected, a dexmedetomidine infusion could be initiated or clonidine 0.1 mg could be administered via an orogastric tube (with repeat dosing as necessary). (See
         <a class="medical medical_review" href="/z/d/html/3864.html" rel="external">
          "Tapering and discontinuing antihypertensive medications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3868.html" rel="external">
          "Perioperative management of hypertension", section on 'Withdrawal syndromes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Disadvantages include potent bradycardic effects such that
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         should be used with caution during a high spinal or epidural block and in patients receiving beta blockers. Also, decreases in HR and BP resolve slowly and may persist even after emergence from general anesthesia [
         <a href="#rid77">
          77
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">
          "Maintenance of general anesthesia: Overview", section on 'Dexmedetomidine'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94537.html" rel="external">
          "Emergence from general anesthesia", section on 'Intravenous agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clonidine
         </strong>
         <strong>
         </strong>
         –
         <strong>
         </strong>
         For patients chronically receiving
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         as part of an antihypertensive regimen, a missed dose on the day of surgery may result in a rebound hypertensive response. This can be avoided by application of a transdermal patch of clonidine during the preoperative period, or by selecting
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         as an anesthetic agent, as noted above.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1818605990">
         <span class="h3">
          Fenoldopam
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8629" href="/z/d/drug information/8629.html" rel="external">
          Fenoldopam
         </a>
         is a selective dopamine receptor agonist that produces systemic vasodilation. It is administered by continuous infusion initially at 0.1 mcg/kg per minute and may be increased up to a maximum dose of 1.6 mcg/kg per minute. Fenoldopam has potentially beneficial effects on renal function, although there are no outcome data proving efficacy for renal protection. In some centers, it is used in high-risk vascular surgery or to treat hypertensive emergencies [
         <a href="#rid79">
          79,80
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">
          "Drugs used for the treatment of hypertensive emergencies", section on 'Fenoldopam'
         </a>
         .)
        </p>
        <p>
         As with other vasodilators,
         <a class="drug drug_general" data-topicid="8629" href="/z/d/drug information/8629.html" rel="external">
          fenoldopam
         </a>
         is avoided in patients with increased ICP. It is also avoided in patients with high intraocular pressure (IOP) such as those with glaucoma [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3624479902">
         <span class="h3">
          Enalaprilat
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="17094" href="/z/d/drug information/17094.html" rel="external">
          Enalaprilat
         </a>
         is the only available IV angiotensin-converting enzyme inhibitor. It is rarely used in the perioperative setting but may be added to other agents for hypertensive emergencies [
         <a href="#rid82">
          82
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">
          "Drugs used for the treatment of hypertensive emergencies", section on 'Enalaprilat'
         </a>
         .)
        </p>
        <p>
         Disadvantages include an unpredictable hypotensive response. It may cause precipitous hypotension in hypovolemic patients with high plasma renin activity. Also,
         <a class="drug drug_general" data-topicid="17094" href="/z/d/drug information/17094.html" rel="external">
          enalaprilat
         </a>
         has a slow onset over 15 to 30 minutes and a long duration of effect.
        </p>
        <p class="headingAnchor" id="H3134584171">
         <span class="h3">
          Diuretics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypertensive patients who are hypervolemic or show signs of pulmonary edema may benefit from diuresis (eg, with administration of IV
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         10 to 20 mg), particularly if the morning dose of a chronically administered diuretic was missed. However, since most vasodilating agents administered in the perioperative setting will temporarily reduce preload, administration of a diuretic is not typically necessary.
        </p>
        <p class="headingAnchor" id="H2514408768">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vasopressors and inotropic agents
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Overview
         </strong>
         –
         <strong>
         </strong>
         Bolus doses and/or continuous infusion of vasopressor and/or inotropic agents are administered to treat hypotension that does not immediately respond to decreasing anesthetic depth and/or fluid administration  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Overview'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adrenergic agents
         </strong>
         –
         <strong>
         </strong>
         Adrenergic agents administered to increase blood pressure (BP) include
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         (administered in bolus doses),
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         (administered either in bolus doses or as an infusion), and the more potent endogenous catecholamines, norepinephrine and epinephrine (administered either in low bolus doses or as an infusion)  (
         <a class="graphic graphic_table graphicRef63100" href="/z/d/graphic/63100.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Adrenergic agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Agents to treat refractory vasoplegia
         </strong>
         –
         <strong>
         </strong>
         Vasopressin administered either in low bolus doses or as an infusion is the agent most commonly used to treat hypotension refractory to administration of adrenergic agents (eg, patients with vasoplegia due to septic shock). Infusions of other vasopressors such as
         <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">
          methylene blue
         </a>
         , angiotensin II,
         <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">
          vitamin C
         </a>
         , or hydroxycobalamin may be necessary to treat vasoplegia unresponsive to high doses of norepinephrine and/or vasopressin  (
         <a class="graphic graphic_table graphicRef126194" href="/z/d/graphic/126194.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="local">
          'Vasopressin'
         </a>
         above and
         <a class="local">
          'Other agents to treat refractory vasoplegia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other inotropic agents
         </strong>
         –
         <strong>
         </strong>
         Infusions of other inotropic drugs may be used to improve support of the circulation in selected patients but are not first-line vasoactive agents for treatment of intraoperative hypotension or other hemodynamic abnormalities. These include the adrenergic agents dopamine,
         <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">
          dobutamine
         </a>
         , and
         <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">
          isoproterenol
         </a>
         , and inodilators such as the phosphodiesterase inhibitor
         <a class="drug drug_general" data-topicid="9652" href="/z/d/drug information/9652.html" rel="external">
          milrinone
         </a>
         and the calcium-sensitizing agent levosimendan. (See
         <a class="local">
          'Other inotropic agents'
         </a>
         above and
         <a class="local">
          'Inodilators'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antihypertensive agents
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Overview
         </strong>
         –
         <strong>
         </strong>
         Bolus doses and/or continuous infusions of antihypertensive agents may be administered to treat hypertension  (
         <a class="graphic graphic_table graphicRef119750" href="/z/d/graphic/119750.html" rel="external">
          table 6
         </a>
         ) if there is insufficient response to rapid increases in anesthetic depth, administration of analgesic agents, or removal of noxious stimuli. (See
         <a class="local">
          'Overview'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Beta blockers
         </strong>
         –
         <strong>
         </strong>
         Beta blockers administered to decrease BP and/or heart rate (HR) include
         <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">
          labetalol
         </a>
         and
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         (administered in bolus doses), as well as
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         (administered either in bolus doses or as an infusion). (See
         <a class="local">
          'Beta blockers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Calcium channel blockers
         </strong>
         –
         <strong>
         </strong>
         Calcium channel blockers that may be administered to decrease BP and systemic vascular resistance (SVR) in the absence of tachycardia include
         <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">
          nicardipine
         </a>
         and
         <a class="drug drug_general" data-topicid="8911" href="/z/d/drug information/8911.html" rel="external">
          clevidipine
         </a>
         (administered either in bolus doses or as an infusion). (See
         <a class="local">
          'Calcium channel blocking agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Direct vasodilators
         </strong>
         –
         <strong>
         </strong>
         Direct vasodilators relax vascular smooth muscle to decrease BP by decreasing SVR and preload, which is often accompanied by a reflex increase in HR. Decreased venous return to the heart reduces preload. Direct arterial dilators include
         <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">
          hydralazine
         </a>
         (administered in bolus doses) and
         <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">
          nitroprusside
         </a>
         (administered as an infusion), while
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         is primarily a venodilator administered either in low bolus doses or as a continuous infusion. During infusion of nitroprusside or nitroglycerin, an intra-arterial catheter is necessary to continuously monitor BP. (See
         <a class="local">
          'Direct vasodilators'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other antihypertensive agents
         </strong>
         –
         <strong>
         </strong>
         Other classes of agents that are less commonly used to lower BP in the intraoperative setting include infusions of
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         (an anesthetic agent and alpha
         <sub>
          2
         </sub>
         -adrenoreceptor agonist with sympatholytic effects administered by infusion) or
         <a class="drug drug_general" data-topicid="8629" href="/z/d/drug information/8629.html" rel="external">
          fenoldopam
         </a>
         (a selective dopamine receptor agonist with potential renoprotective and vasodilatory effects). (See
         <a class="local">
          'Other antihypertensive agents'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Overgaard CB, Dzavík V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation 2008; 118:1047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farag E, Makarova N, Argalious M, et al. Vasopressor Infusion During Prone Spine Surgery and Acute Renal Injury: A Retrospective Cohort Analysis. Anesth Analg 2019; 129:896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hiltebrand LB, Koepfli E, Kimberger O, et al. Hypotension during fluid-restricted abdominal surgery: effects of norepinephrine treatment on regional and microcirculatory blood flow in the intestinal tract. Anesthesiology 2011; 114:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi S, Endou M, Sakuraya F, et al. The sympathomimetic actions of l-ephedrine and d-pseudoephedrine: direct receptor activation or norepinephrine release? Anesth Analg 2003; 97:1239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alsufyani HA, Docherty JR. Direct and indirect effects of ephedrine on heart rate and blood pressure in vehicle-treated and sympathectomised male rats. Eur J Pharmacol 2018; 825:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goertz AW, Hübner C, Seefelder C, et al. The effect of ephedrine bolus administration on left ventricular loading and systolic performance during high thoracic epidural anesthesia combined with general anesthesia. Anesth Analg 1994; 78:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CHEN KK, SCHMIDT CF. The action and clinical use of ephedrine, an alkaloid isolated from the Chinese drug ma huang; historical document. Ann Allergy 1959; 17:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koch KU, Mikkelsen IK, Aanerud J, et al. Ephedrine versus Phenylephrine Effect on Cerebral Blood Flow and Oxygen Consumption in Anesthetized Brain Tumor Patients: A Randomized Clinical Trial. Anesthesiology 2020; 133:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nissen P, Brassard P, Jørgensen TB, Secher NH. Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension. Neurocrit Care 2010; 12:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meng L, Cannesson M, Alexander BS, et al. Effect of phenylephrine and ephedrine bolus treatment on cerebral oxygenation in anaesthetized patients. Br J Anaesth 2011; 107:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soeding PF, Hoy S, Hoy G, et al. Effect of phenylephrine on the haemodynamic state and cerebral oxygen saturation during anaesthesia in the upright position. Br J Anaesth 2013; 111:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Futier E, Lefrant JY, Guinot PG, et al. Effect of Individualized vs Standard Blood Pressure Management Strategies on Postoperative Organ Dysfunction Among High-Risk Patients Undergoing Major Surgery: A Randomized Clinical Trial. JAMA 2017; 318:1346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanno LK, Fillard A, Landry Q, et al. Ephedrine-induced erythrodermia: Clinical diagnostic procedure and cross-sensitivity. Contact Dermatitis 2018; 79:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwinn DA, Reves JG. Time course and hemodynamic effects of alpha-1-adrenergic bolus administration in anesthetized patients with myocardial disease. Anesth Analg 1989; 68:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goertz AW, Lindner KH, Schütz W, et al. Influence of phenylephrine bolus administration on left ventricular filling dynamics in patients with coronary artery disease and patients with valvular aortic stenosis. Anesthesiology 1994; 81:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goertz AW, Lindner KH, Seefelder C, et al. Effect of phenylephrine bolus administration on global left ventricular function in patients with coronary artery disease and patients with valvular aortic stenosis. Anesthesiology 1993; 78:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adefurin A, Ghimire LV, Kohli U, et al. Genetic variation in the alpha1B-adrenergic receptor and vascular response. Pharmacogenomics J 2017; 17:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adefurin A, Ghimire LV, Kohli U, et al. Genetic variation in the α1A-adrenergic receptor and phenylephrine-mediated venoconstriction. Pharmacogenomics J 2015; 15:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talke P, Stapelfeldt C, Lobo E, et al. Alpha-2B adrenoceptor polymorphism and peripheral vasoconstriction. Pharmacogenet Genomics 2005; 15:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen M, Staalsoe JM, Ullum H, et al. The Gly16 Allele of the Gly16Arg Single-Nucleotide Polymorphism in the β₂-Adrenergic Receptor Gene Augments Perioperative Use of Vasopressors: A Retrospective Cohort Study. Anesth Analg 2016; 122:1385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vallée F, Passouant O, Le Gall A, et al. Norepinephrine reduces arterial compliance less than phenylephrine when treating general anesthesia-induced arterial hypotension. Acta Anaesthesiol Scand 2017; 61:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thiele RH, Nemergut EC, Lynch C 3rd. The clinical implications of isolated alpha(1) adrenergic stimulation. Anesth Analg 2011; 113:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thiele RH, Nemergut EC, Lynch C 3rd. The physiologic implications of isolated alpha(1) adrenergic stimulation. Anesth Analg 2011; 113:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goertz AW, Schmidt M, Seefelder C, et al. The effect of phenylephrine bolus administration on left ventricular function during isoflurane-induced hypotension. Anesth Analg 1993; 77:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maas JJ, Pinsky MR, de Wilde RB, et al. Cardiac output response to norepinephrine in postoperative cardiac surgery patients: interpretation with venous return and cardiac function curves. Crit Care Med 2013; 41:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rebet O, Andremont O, Gérard JL, et al. Preload dependency determines the effects of phenylephrine on cardiac output in anaesthetised patients: A prospective observational study. Eur J Anaesthesiol 2016; 33:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magder S. Phenylephrine and tangible bias. Anesth Analg 2011; 113:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joosten A, Rinehart J, Van der Linden P, et al. Computer-assisted Individualized Hemodynamic Management Reduces Intraoperative Hypotension in Intermediate- and High-risk Surgery: A Randomized Controlled Trial. Anesthesiology 2021; 135:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mets B. Should Norepinephrine, Rather than Phenylephrine, Be Considered the Primary Vasopressor in Anesthetic Practice? Anesth Analg 2016; 122:1707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furrer MA, Schneider MP, Löffel LM, et al. Impact of intra-operative fluid and noradrenaline administration on early postoperative renal function after cystectomy and urinary diversion: A retrospective observational cohort study. Eur J Anaesthesiol 2018; 35:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aykanat VM, Myles PS, Weinberg L, et al. Low-Concentration Norepinephrine Infusion for Major Surgery: A Safety and Feasibility Pilot Randomized Controlled Trial. Anesth Analg 2022; 134:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           French WB, Rothstein WB, Scott MJ. Time to Use Peripheral Norepinephrine in the Operating Room. Anesth Analg 2021; 133:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legrand M, Kothari R, Fong N, et al. Norepinephrine versus phenylephrine for treating hypotension during general anaesthesia in adult patients undergoing major noncardiac surgery: a multicentre, open-label, cluster-randomised, crossover, feasibility, and pilot trial. Br J Anaesth 2023; 130:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ngan Kee WD. A Random-allocation Graded Dose-Response Study of Norepinephrine and Phenylephrine for Treating Hypotension during Spinal Anesthesia for Cesarean Delivery. Anesthesiology 2017; 127:934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guinot PG, Longrois D, Kamel S, et al. Ventriculo-Arterial Coupling Analysis Predicts the Hemodynamic Response to Norepinephrine in Hypotensive Postoperative Patients: A Prospective Observational Study. Crit Care Med 2018; 46:e17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasanin AM, Amin SM, Agiza NA, et al. Norepinephrine Infusion for Preventing Postspinal Anesthesia Hypotension during Cesarean Delivery: A Randomized Dose-finding Trial. Anesthesiology 2019; 130:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gelman S. Using small doses of norepinephrine or phenylephrine during the peri-operative period. Eur J Anaesthesiol 2022; 39:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pancaro C, Shah N, Pasma W, et al. Risk of Major Complications After Perioperative Norepinephrine Infusion Through Peripheral Intravenous Lines in a Multicenter Study. Anesth Analg 2020; 131:1060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loubani OM, Green RS. A systematic review of extravasation and local tissue injury from administration of vasopressors through peripheral intravenous catheters and central venous catheters. J Crit Care 2015; 30:653.e9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardenas-Garcia J, Schaub KF, Belchikov YG, et al. Safety of peripheral intravenous administration of vasoactive medication. J Hosp Med 2015; 10:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Araiza A, Duran M, Varon J. Administration of vasopressors through peripheral venous catheters. CMAJ 2022; 194:E739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Son HW, Park SH, Cho HO, et al. Epinephrine-induced lactic acidosis in orthognathic surgery: a report of two cases. J Korean Assoc Oral Maxillofac Surg 2016; 42:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Totaro RJ, Raper RF. Epinephrine-induced lactic acidosis following cardiopulmonary bypass. Crit Care Med 1997; 25:1693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treschan TA, Peters J. The vasopressin system: physiology and clinical strategies. Anesthesiology 2006; 105:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park KS, Yoo KY. Role of vasopressin in current anesthetic practice. Korean J Anesthesiol 2017; 70:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Currigan DA, Hughes RJ, Wright CE, et al. Vasoconstrictor responses to vasopressor agents in human pulmonary and radial arteries: an in vitro study. Anesthesiology 2014; 121:930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace AW, Tunin CM, Shoukas AA. Effects of vasopressin on pulmonary and systemic vascular mechanics. Am J Physiol 1989; 257:H1228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leather HA, Segers P, Berends N, et al. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med 2002; 30:2548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahn JM, Kress JP, Hall JB. Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. Crit Care Med 2002; 30:1899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandez SJ, Barakat I, Ziogas J, et al. Association of copeptin, a surrogate marker of arginine vasopressin, with cerebral vasospasm and delayed ischemic neurologic deficit after aneurysmal subarachnoid hemorrhage. J Neurosurg 2018; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy B, Fritz C, Tahon E, et al. Vasoplegia treatments: the past, the present, and the future. Crit Care 2018; 22:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ortoleva JP, Cobey FC. A Systematic Approach to the Treatment of Vasoplegia Based on Recent Advances in Pharmacotherapy. J Cardiothorac Vasc Anesth 2019; 33:1310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feih JT, Rinka JRG, Zundel MT. Methylene Blue Monotherapy Compared With Combination Therapy With Hydroxocobalamin for the Treatment of Refractory Vasoplegic Syndrome: ARetrospective Cohort Study. J Cardiothorac Vasc Anesth 2019; 33:1301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furnish C, Mueller SW, Kiser TH, et al. Hydroxocobalamin Versus Methylene Blue for Vasoplegic Syndrome in Cardiothoracic Surgery: A Retrospective Cohort. J Cardiothorac Vasc Anesth 2020; 34:1763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jentzer JC, Vallabhajosyula S, Khanna AK, et al. Management of Refractory Vasodilatory Shock. Chest 2018; 154:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khanna A, English SW, Wang XS, et al. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med 2017; 377:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busse LW, Wang XS, Chalikonda DM, et al. Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety. Crit Care Med 2017; 45:1285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wieruszewski PM, Nei SD, Maltais S, et al. Vitamin C for Vasoplegia After Cardiopulmonary Bypass: A Case Series. A A Pract 2018; 11:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chow JH, Abuelkasem E, Sankova S, et al. Reversal of Vasodilatory Shock: Current Perspectives on Conventional, Rescue, and Emerging Vasoactive Agents for the Treatment of Shock. Anesth Analg 2020; 130:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beattie WS, Wijeysundera DN, Karkouti K, et al. Acute surgical anemia influences the cardioprotective effects of beta-blockade: a single-center, propensity-matched cohort study. Anesthesiology 2010; 112:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ragoonanan TE, Beattie WS, Mazer CD, et al. Metoprolol reduces cerebral tissue oxygen tension after acute hemodilution in rats. Anesthesiology 2009; 111:988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryu JH, Apfel CC, Whelan R, et al. Comparative prophylactic and therapeutic effects of intravenous labetalol 0.4 mg/kg and nicardipine 20 μg/kg on hypertensive responses to endotracheal intubation in patients undergoing elective surgeries with general anesthesia: a prospective, randomized, double-blind study. Clin Ther 2012; 34:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poveda-Jaramillo R, Monaco F, Zangrillo A, Landoni G. Ultra-Short-Acting β-Blockers (Esmolol and Landiolol) in the Perioperative Period and in Critically Ill Patients. J Cardiothorac Vasc Anesth 2018; 32:1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Syed YY. Landiolol: A Review in Tachyarrhythmias. Drugs 2018; 78:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheung AT, Guvakov DV, Weiss SJ, et al. Nicardipine intravenous bolus dosing for acutely decreasing arterial blood pressure during general anesthesia for cardiac operations: pharmacokinetics, pharmacodynamics, and associated effects on left ventricular function. Anesth Analg 1999; 89:1116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bebawy JF, Houston CC, Kosky JL, et al. Nicardipine is superior to esmolol for the management of postcraniotomy emergence hypertension: a randomized open-label study. Anesth Analg 2015; 120:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hecht JP, Richards PG. Continuous-Infusion Labetalol vs Nicardipine for Hypertension Management in Stroke Patients. J Stroke Cerebrovasc Dis 2018; 27:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keating GM. Clevidipine: a review of its use for managing blood pressure in perioperative and intensive care settings. Drugs 2014; 74:1947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinosa A, Ripollés-Melchor J, Casans-Francés R, et al. Perioperative Use of Clevidipine: A Systematic Review and Meta-Analysis. PLoS One 2016; 11:e0150625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenfeldt Z, Conklen K, Jones B, et al. Comparison of Nicardipine with Clevidipine in the Management of Hypertension in Acute Cerebrovascular Diseases. J Stroke Cerebrovasc Dis 2018; 27:2067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finger JR, Kurczewski LM, Brophy GM. Clevidipine Versus Nicardipine for Acute Blood Pressure Reduction in a Neuroscience Intensive Care Population. Neurocrit Care 2017; 26:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allison TA, Bowman S, Gulbis B, et al. Comparison of Clevidipine and Nicardipine for Acute Blood Pressure Reduction in Patients With Stroke. J Intensive Care Med 2019; 34:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powers DR, Papadakos PJ, Wallin JD. Parenteral hydralazine revisited. J Emerg Med 1998; 16:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anjou-Lindskog E, Broman L, Holmgren A. Effects of nitroglycerin on central haemodynamics and VA/Q distribution early after coronary bypass surgery. Acta Anaesthesiol Scand 1982; 26:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pirracchio R, Parenica J, Resche Rigon M, et al. The effectiveness of inodilators in reducing short term mortality among patient with severe cardiogenic shock: a propensity-based analysis. PLoS One 2013; 8:e71659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rong LQ, Rahouma M, Abouarab A, et al. Intravenous and Inhaled Milrinone in Adult Cardiac Surgery Patients: A Pairwise and Network Meta-Analysis. J Cardiothorac Vasc Anesth 2019; 33:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dutta A, Sethi N, Sood J, et al. The Effect of Dexmedetomidine on Propofol Requirements During Anesthesia Administered by Bispectral Index-Guided Closed-Loop Anesthesia Delivery System: A Randomized Controlled Study. Anesth Analg 2019; 129:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colin PJ, Hannivoort LN, Eleveld DJ, et al. Dexmedetomidine pharmacodynamics in healthy volunteers: 2. Haemodynamic profile. Br J Anaesth 2017; 119:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 2001; 345:1548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bove T, Zangrillo A, Guarracino F, et al. Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial. JAMA 2014; 312:2244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elliott WJ, Karnezis TA, Silverman RA, et al. Intraocular pressure increases with fenoldopam, but not nitroprusside, in hypertensive humans. Clin Pharmacol Ther 1991; 49:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirschl MM, Binder M, Bur A, et al. Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive crises. Arch Intern Med 1995; 155:2217.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 141346 Version 5.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18765387" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31425235" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Vasopressor Infusion During Prone Spine Surgery and Acute Renal Injury: A Retrospective Cohort Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21307765" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Hypotension during fluid-restricted abdominal surgery: effects of norepinephrine treatment on regional and microcirculatory blood flow in the intestinal tract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14570629" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The sympathomimetic actions of l-ephedrine and d-pseudoephedrine: direct receptor activation or norepinephrine release?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29454610" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Direct and indirect effects of ephedrine on heart rate and blood pressure in vehicle-treated and sympathectomised male rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8267145" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The effect of ephedrine bolus administration on left ventricular loading and systolic performance during high thoracic epidural anesthesia combined with general anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13809594" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The action and clinical use of ephedrine, an alkaloid isolated from the Chinese drug ma huang; historical document.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32482999" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Ephedrine versus Phenylephrine Effect on Cerebral Blood Flow and Oxygen Consumption in Anesthetized Brain Tumor Patients: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19957053" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21642644" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Effect of phenylephrine and ephedrine bolus treatment on cerebral oxygenation in anaesthetized patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23518801" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Effect of phenylephrine on the haemodynamic state and cerebral oxygen saturation during anaesthesia in the upright position.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28973220" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effect of Individualized vs Standard Blood Pressure Management Strategies on Postoperative Organ Dysfunction Among High-Risk Patients Undergoing Major Surgery: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29573348" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Ephedrine-induced erythrodermia: Clinical diagnostic procedure and cross-sensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2541637" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Time course and hemodynamic effects of alpha-1-adrenergic bolus administration in anesthetized patients with myocardial disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8042810" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Influence of phenylephrine bolus administration on left ventricular filling dynamics in patients with coronary artery disease and patients with valvular aortic stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8489054" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Effect of phenylephrine bolus administration on global left ventricular function in patients with coronary artery disease and patients with valvular aortic stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27089938" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Genetic variation in the alpha1B-adrenergic receptor and vascular response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25421140" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Genetic variation in theα1A-adrenergic receptor and phenylephrine-mediated venoconstriction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15864138" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Alpha-2B adrenoceptor polymorphism and peripheral vasoconstriction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26771271" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The Gly16 Allele of the Gly16Arg Single-Nucleotide Polymorphism in theβ₂-Adrenergic Receptor Gene Augments Perioperative Use of Vasopressors: A Retrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28543052" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Norepinephrine reduces arterial compliance less than phenylephrine when treating general anesthesia-induced arterial hypotension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21519053" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The clinical implications of isolated alpha(1) adrenergic stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21519050" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The physiologic implications of isolated alpha(1) adrenergic stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8346819" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The effect of phenylephrine bolus administration on left ventricular function during isoflurane-induced hypotension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23128382" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Cardiac output response to norepinephrine in postoperative cardiac surgery patients: interpretation with venous return and cardiac function curves.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27164015" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Preload dependency determines the effects of phenylephrine on cardiac output in anaesthetised patients: A prospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21788324" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Phenylephrine and tangible bias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33951140" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Computer-assisted Individualized Hemodynamic Management Reduces Intraoperative Hypotension in Intermediate- and High-risk Surgery: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27101504" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Should Norepinephrine, Rather than Phenylephrine, Be Considered the Primary Vasopressor in Anesthetic Practice?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29652680" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Impact of intra-operative fluid and noradrenaline administration on early postoperative renal function after cystectomy and urinary diversion: A retrospective observational cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34872102" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Low-Concentration Norepinephrine Infusion for Major Surgery: A Safety and Feasibility Pilot Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33886514" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Time to Use Peripheral Norepinephrine in the Operating Room.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36925330" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Norepinephrine versus phenylephrine for treating hypotension during general anaesthesia in adult patients undergoing major noncardiac surgery: a multicentre, open-label, cluster-randomised, crossover, feasibility, and pilot trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28872480" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A Random-allocation Graded Dose-Response Study of Norepinephrine and Phenylephrine for Treating Hypotension during Spinal Anesthesia for Cesarean Delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29019850" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Ventriculo-Arterial Coupling Analysis Predicts the Hemodynamic Response to Norepinephrine in Hypotensive Postoperative Patients: A Prospective Observational Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30335625" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Norepinephrine Infusion for Preventing Postspinal Anesthesia Hypotension during Cesarean Delivery: A Randomized Dose-finding Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35759290" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Using small doses of norepinephrine or phenylephrine during the peri-operative period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32925324" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Risk of Major Complications After Perioperative Norepinephrine Infusion Through Peripheral Intravenous Lines in a Multicenter Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25669592" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A systematic review of extravasation and local tissue injury from administration of vasopressors through peripheral intravenous catheters and central venous catheters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26014852" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Safety of peripheral intravenous administration of vasoactive medication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35636752" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Administration of vasopressors through peripheral venous catheters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27847739" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Epinephrine-induced lactic acidosis in orthognathic surgery: a report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9377884" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Epinephrine-induced lactic acidosis following cardiopulmonary bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16931995" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The vasopressin system: physiology and clinical strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28580075" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Role of vasopressin in current anesthetic practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25198173" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Vasoconstrictor responses to vasopressor agents in human pulmonary and radial arteries: an in vitro study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2801982" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Effects of vasopressin on pulmonary and systemic vascular mechanics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12441768" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12163813" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Skin necrosis after extravasation of low-dose vasopressin administered for septic shock.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29726784" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Association of copeptin, a surrogate marker of arginine vasopressin, with cerebral vasospasm and delayed ischemic neurologic deficit after aneurysmal subarachnoid hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29486781" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Vasoplegia treatments: the past, the present, and the future.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30598380" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : A Systematic Approach to the Treatment of Vasoplegia Based on Recent Advances in Pharmacotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30606508" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Methylene Blue Monotherapy Compared With Combination Therapy With Hydroxocobalamin for the Treatment of Refractory Vasoplegic Syndrome: ARetrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32115360" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Hydroxocobalamin Versus Methylene Blue for Vasoplegic Syndrome in Cardiothoracic Surgery: A Retrospective Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29329694" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Management of Refractory Vasodilatory Shock.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28528561" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Angiotensin II for the Treatment of Vasodilatory Shock.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28489648" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29634537" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Vitamin C for Vasoplegia After Cardiopulmonary Bypass: A Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31348056" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Reversal of Vasodilatory Shock: Current Perspectives on Conventional, Rescue, and Emerging Vasoactive Agents for the Treatment of Shock.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20032700" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Acute surgical anemia influences the cardioprotective effects of beta-blockade: a single-center, propensity-matched cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19809291" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Metoprolol reduces cerebral tissue oxygen tension after acute hemodilution in rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22364823" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Comparative prophylactic and therapeutic effects of intravenous labetalol 0.4 mg/kg and nicardipine 20μg/kg on hypertensive responses to endotracheal intubation in patients undergoing elective surgeries with general anesthesia: a prospective, randomized, double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29398384" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Ultra-Short-Actingβ-Blockers (Esmolol and Landiolol) in the Perioperative Period and in Critically Ill Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29470800" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Landiolol: A Review in Tachyarrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10553821" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Nicardipine intravenous bolus dosing for acutely decreasing arterial blood pressure during general anesthesia for cardiac operations: pharmacokinetics, pharmacodynamics, and associated effects on left ventricular function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25296247" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Nicardipine is superior to esmolol for the management of postcraniotomy emergence hypertension: a randomized open-label study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29092768" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Continuous-Infusion Labetalol vs Nicardipine for Hypertension Management in Stroke Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25312594" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Clevidipine: a review of its use for managing blood pressure in perioperative and intensive care settings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27018586" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Perioperative Use of Clevidipine: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29627171" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Comparison of Nicardipine with Clevidipine in the Management of Hypertension in Acute Cerebrovascular Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27995512" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Clevidipine Versus Nicardipine for Acute Blood Pressure Reduction in a Neuroscience Intensive Care Population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28820038" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Comparison of Clevidipine and Nicardipine for Acute Blood Pressure Reduction in Patients With Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9543400" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Parenteral hydralazine revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6815975" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Effects of nitroglycerin on central haemodynamics and VA/Q distribution early after coronary bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23977106" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : The effectiveness of inodilators in reducing short term mortality among patient with severe cardiogenic shock: a propensity-based analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30287183" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Intravenous and Inhaled Milrinone in Adult Cardiac Surgery Patients: A Pairwise and Network Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29787410" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : The Effect of Dexmedetomidine on Propofol Requirements During Anesthesia Administered by Bispectral Index-Guided Closed-Loop Anesthesia Delivery System: A Randomized Controlled Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28854543" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Dexmedetomidine pharmacodynamics in healthy volunteers: 2. Haemodynamic profile.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11794223" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25265449" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1672512" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Intraocular pressure increases with fenoldopam, but not nitroprusside, in hypertensive humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7487244" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive crises.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
